← Back to Search

Cell Therapy

Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Led By Veronika Bachanova, MD, PhD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post infusion
Awards & highlights

Study Summary

This trial is testing a new therapy for cancer using expanded natural killer cells. The goal is to find the maximum tolerated dose while maintaining safety.

Eligible Conditions
  • Mediastinal Lymphoma
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • B-Cell Non-Hodgkin Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)
Occurrence of any grade 4 or greater suspected adverse reaction
Secondary outcome measures
Number of patients alive without progression
Occurrence of disease response
Occurrence of treatment related mortality (TRM)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Non-Hodgkin LymphomaExperimental Treatment1 Intervention
After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
Group II: Multiple MyelomaExperimental Treatment1 Intervention
After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Natural Killer Cell
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
271 Previous Clinical Trials
14,586 Total Patients Enrolled
Veronika Bachanova, MD, PhDPrincipal InvestigatorUniversity of Minnesota
2 Previous Clinical Trials
162 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
2017. "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03019666.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top